The therapeutic application of Пропазин (Promazine) is used to provide a notable sedative effect, applied within specific clinical contexts to manage acute behavioral instability and associated symptoms. The medication is primarily associated with the short-term treatment of disturbed behavior. The benefit provided is focused on providing supportive relief for acute instability and related symptomatic burden.

Promazine is commonly used in conditions characterized by periods of heightened symptoms such as severe psychomotor agitation—a state of intense restlessness and purposeless, excessive movement—and is relevant in situations where symptoms related to heightened physiological activity, such as extreme restlessness, high emotional distress, and erratic, disturbed behavior patterns, become overwhelming and create noticeable functional strain. The medication is commonly used to help with managing agitation and severe restlessness in adults and the elderly.

The medication offers short-term symptomatic support, generally in adults, for severe restlessness and agitation. By assisting with the distress associated with severe restlessness, Promazine may assist with maintaining functional stability for a temporary period and supports a more manageable experience during challenging acute episodes.

---

Quick Fact: Symptomatic Support for Restlessness
Promazine helps address severe restlessness and psychomotor agitation, and may assist with a calming effect that supports stability in acute scenarios.

Eligibility for Promazine (Пропазин) Use

Official regulatory documents define strict population eligibility for Promazine, classifying individuals into groups permitted to use the medicine, groups for whom use is restricted, and groups who must not use the medicine.

Classification	Population Status
Populations Allowed	Adults for documented use in agitation; Older adults (geriatric) for agitation/restlessness, but use is conditional and requires caution.
Not Recommended/Restricted	Pediatric population (children); Pregnancy, especially the first three months.

Absolute Contraindications (Must Not Use)

Promazine is formally contraindicated and must not be used in the following populations:

• Patients with known hypersensitivity to Promazine or other phenothiazines.
• Individuals in a coma or with severe Central Nervous System (CNS) depression.
• Patients with bone marrow depression or phaeochromocytoma.
• Individuals who are breastfeeding (lactation).

Condition-Specific Restrictions (Use with Caution)

Use is highly restricted and requires caution in patients with pre-existing conditions that may increase susceptibility to adverse effects, including renal failure, liver dysfunction, epilepsy or seizure risk, cardiac disease, and severe respiratory disease. The medicine is not licensed for treating dementia-related behavioural disturbances in the elderly.

Interactions with other medicines and products

Promazine's interaction profile is formally documented, largely reflecting its classification as a phenothiazine neuroleptic. Co-administration with other Central Nervous System (CNS) depressants (including opioid analgesics, hypnotics, and general anesthetics) is documented to cause pharmacodynamic potentiation, resulting in a significantly increased or intensified sedative action.

Documented Interaction Constraints

Interaction Type	Interacting Substance(s)	Official Constraint/Outcome
Contraindicated/Avoidance	Large doses of other CNS Depressants; Alcohol (Ethanol); MAOIs	Formally noted for avoidance; Alcohol should be avoided during treatment; MAOIs must be avoided for 14 days previously (timing rule).
Pharmacodynamic	Anticholinergic Agents; Antihypertensives	Reinforcement of antimuscarinic side effects; Enhanced hypotensive effect.
Pharmacokinetic	Antacids (Aluminum Hydroxide)	Reduced absorption, leading to decreased Promazine serum concentration.
Pharmacokinetic	Metabolic Inhibitors/Inducers	Agents inhibiting Promazine metabolism (e.g., Abiraterone) increase serum concentration; inducers decrease serum concentration.

Promazine may also lower the convulsive threshold, which is a relevant consideration when co-administered with antiepileptic agents. Furthermore, the regulatory documents note that elderly patients are more susceptible to anticholinergic and hypotensive effects arising from interactions.

How Пропазин Works

The action of Promazine is defined by its multi-receptor antagonism, fundamentally dampening activity across several key neurotransmitter systems simultaneously. This leads to a profound modulation of central and autonomic physiological responses.

---

Central Arousal Pathway Dampening

The primary mechanism for the drug's immediate physiological effect is the antagonism of central histamine H1 receptors within the brain's arousal centers, combined with the blockade of alpha1-adrenergic receptors. This dual action initiates a rapid cascade of central nervous system (CNS) depression, leading directly to the primary physiological consequence of profound sedation.

---

Modulation of Psychomotor Signaling

Promazine acts as an antagonist at central dopamine D2 receptors, particularly in the mesolimbic pathway, thereby modifying the signaling dynamics associated with high emotional drive. This specific action modulates neural pathways and contributes to the reduced psychomotor activity component of the drug's physiological profile, though its D2 receptor affinity is lower relative to its other mechanistic targets.

---

Autonomic and Cholinergic Interruption

The drug's widespread antagonism of muscarinic acetylcholine receptors and peripheral alpha1-adrenergic receptors interrupts the normal functions of the autonomic nervous system. This mechanistic domain contributes to the overall CNS depressant state, resulting in physiological changes such as altered vascular tone and glandular secretions.

Пропазин (Promazine) is officially administered via two primary routes depending on the clinical scenario. It is available for oral use as both tablets and an oral solution or syrup. For acute and specialized management settings, the medicine may also be given via intramuscular (IM) injection.

The use of Promazine is governed by the principle of short-term administration, intended only as an adjunct to management. Treatment must be initiated using the lowest effective dose and continued for the shortest duration possible. For adults, the typical oral dosing ranges from 100 mg to 200 mg per single dose. This dose is scheduled to be administered up to four times daily, establishing regular intervals of approximately six to eight hours between administrations.

A highly important procedural condition is the requirement for close professional supervision when starting treatment and whenever a dosage adjustment is needed. The process requires gradually increasing the initial dose until the effective response is reached. Specific dosing rules apply to certain populations: Older adults must use a significantly lower starting dose, beginning at 25 mg per dose, with a maximum of 50 mg four times daily. Promazine is not recommended for use in children. When treatment is discontinued, the process requires gradual withdrawal.

Research Evidence / Overview of Studies for Пропазин

---

Evidence for use in Acute Agitation and Disturbed Behavior

Promazine (Пропазин) was evaluated in research involving acute agitation and disturbed behavior in adults. Research in this area primarily involves short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies research examined the time required for symptom severity to be measured and monitored outcomes related to systemic or functional imbalance and behavioral outcomes capturing phases of heightened symptom activity in a controlled emergency setting.

Studies monitored patient response over very short defined time intervals, typically measured in minutes or a few hours. These findings describe patterns observed in the studies that are focused on measuring rapid symptomatic change. Many trials research examined Promazine as part of a combination regimen alongside other medications, meaning comparative evidence is lacking for Promazine as a single agent against various other widely used treatments.

---

Long-term Studies and Follow-up Data

The available evidence primarily focuses on Promazine's role in trials assessing short-term or episodic symptom patterns. The typical observation period for these studies was evaluated in settings like emergency departments or acute psychiatric units, where follow-up durations were limited. Because the drug was studied for acute intervention, long-term effects are not fully established by extensive clinical trials.

Evidence is limited regarding the durability of the initial calming response. Research provides context but not individual predictions about the duration of the drug’s overall influence on outcomes reflecting daily functioning or activity level beyond the immediate crisis.

---

Key Limitations and Areas of Research Uncertainty

The research base for Promazine has several factors that limit the overall certainty of the evidence. Much of the clinical data originates from older studies and trials that utilized sample sizes were modest. Evidence quality varies across studies due to the age and size of the trials.

Furthermore, a significant research limitation is the frequent study of Promazine in combination with other agents. The specific contribution of Promazine when used alone (monotherapy) is not as well characterized by recent, large-scale RCTs; the research base primarily involves combination protocols. Evidence highlights what is known — and what is still uncertain about how these medicines with a longer history of use fit into modern acute care protocols.

Key Studies & References

1. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone

Common questions about Пропазин (FAQ)

Q: How quickly should I feel the effects of Пропазин?

A: Clinical information suggests that the effects of Promazine, or drugs belonging to the same pharmacological class, can start to be noticeable relatively quickly. After oral administration, clinical effects may begin to appear within approximately 20 minutes.

Q: What is the typical duration of action for a dose of Пропазин?

A: Regulatory information indicates that the duration of action for this class of medicine typically lasts between four and six hours. However, the effects may sometimes persist for up to 12 hours.

Q: What are the most common mild side effects of Пропазин?

A: According to official information on this class of drug, the most frequently documented side effects include drowsiness, dizziness, dry mouth, and constipation. Awareness of these effects is important when initiating treatment.

Q: Can Пропазин cause dry mouth, and how can I manage it?

A: Yes, dry mouth is a documented side effect, which is related to the drug’s anticholinergic properties. Official regulatory sources list the occurrence of the side effect but do not provide specific patient management or relief tips.

Q: Is weight gain a possible side effect of taking Пропазин?

A: Weight gain is a recognized side effect for some medications belonging to the broader first-generation antipsychotic class. Concerns regarding this side effect should be discussed with a healthcare provider.

Q: Is it safe to drive while taking Пропазин?

A: Official warnings strongly advise against driving a car or operating machinery if the medicine causes sleepiness, dizziness, or blurred vision. This caution is especially relevant when initiating treatment or following a dosage change.

Q: Does Пропазин interact with common over-the-counter pain relievers?

A: Official information warns that combining Promazine with opioid pain relievers can significantly increase the sedative effect. Caution is generally advised with any over-the-counter medication that causes drowsiness or contains ingredients that may interact with the drug.

Q: Is Пропазин considered an older or newer generation of psychiatric medication?

A: Promazine is officially classified as a neuroleptic or a first-generation antipsychotic agent. This classification places it among the older categories of psychiatric medications.

Q: Is it normal to feel dizzy or lightheaded when starting Пропазин?

A: Yes, dizziness and lightheadedness are documented as common side effects of the medicine. These feelings may be a symptom of drug-induced hypotension (low blood pressure), which the medicine is known to cause.

Q: Can Пропазин affect blood pressure?

A: Official information confirms that the drug can affect blood pressure. It is documented to cause hypotension, or abnormally low blood pressure, which is generally considered a dose-related effect.

Q: Can taking Пропазин make me more sensitive to the sun?

A: The medicine can increase skin sensitivity to light from the sun, sunlamps, and tanning beds (photosensitivity). Protective clothing and sunscreen are noted in official warnings as necessary precautions when sun exposure occurs.

Q: What happens if Пропазин is taken with other sedative medications?

A: Official documents warn that taking the drug with other Central Nervous System (CNS) depressants, such as hypnotics or general anesthetics, may lead to pharmacodynamic potentiation. This results in a significantly increased or intensified sedative action.

Q: Is there a generic version of Пропазин available?

A: Yes, the drug Promazine is typically available in its generic form, known as Promazine hydrochloride. Generic availability may vary by region.

Q: Why is Пропазин sometimes used before a surgical procedure?

A: The medicine is sometimes used in pre-operative and post-operative medical settings. It is indicated for use to provide sedation and to help prevent and control feelings of nausea and vomiting associated with anesthesia and surgery.

Q: Are there any herbal supplements that should be avoided when using Пропазин?

A: While specific herbal supplements are not universally listed in regulatory warnings, official guidance notes that healthcare providers should be informed about all medicines and herbs being taken. This is necessary because there may be insufficient data to confirm that all herbal remedies are safe to use with the drug.

Q: How does Пропазин differ from other antipsychotic medications like Haloperidol?

A: Promazine is pharmacologically distinguished by its sedative-dominant profile among first-generation antipsychotics. Regulatory documents note that it has relatively weaker antipsychotic effects compared to some other medicines in the same phenothiazine class.

Q: Why do some people say Пропазин makes them feel restless?

A: For some individuals, the drug's action on dopamine receptors can paradoxically lead to restlessness or an inability to stay still, known as akathisia. This is classified as a type of extrapyramidal side effect.

Q: Can Пропазин affect cognitive function or memory?

A: The drug possesses anticholinergic properties, and high anticholinergic burden scores for this class of medicine are associated with an increased risk of cognitive impairment. This effect should be monitored by a healthcare professional.

Q: Is Пропазин used for conditions other than psychiatric disorders?

A: Yes, drugs in the same class as Promazine are officially used for purposes beyond acute psychiatric agitation. These uses include managing nausea and vomiting (antiemetic) and providing general sedation in various medical settings.

Q: Has Пропазин been studied in pregnant women?

A: Promazine is not generally recommended for use during pregnancy, particularly in the first three months. While the specific clinical trial data for Promazine may not be detailed in the official label, some related phenothiazine drugs have been studied for their use in pregnancy sickness.

Q: Can Пропазин cause problems with body temperature regulation?

A: Official safety information indicates that the drug can influence the body's thermoregulation mechanisms. Potential adverse effects include an increased risk of hypothermia (abnormally low body temperature) or difficulty regulating body temperature.

Q: Is there a link between Пропазин and liver function issues?

A: Liver function is a relevant safety consideration. Liver dysfunction is listed as a pre-existing condition requiring caution before using the medicine. Additionally, Hepatobiliary Disorders is a category for possible adverse reactions linked to this class of drug.

Q: Does Пропазин impact sleep patterns or cause insomnia?

A: Insomnia (trouble sleeping) is listed in official documents as a potential acute withdrawal symptom. This may occur if the medicine is stopped suddenly rather than being gradually tapered off as directed by a healthcare provider.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Promazine hydrochloride.

Storage Condition	Official Requirement
Temperature	Tablets must be stored at controlled room temperature (20 C–25 C). Oral syrup must be stored below 25 C.
Light Protection	Both the tablets and the oral syrup must be protected from light; tablets require a light-resistant container.
Container	Tablets must be kept in a tightly closed container. The syrup is dispensed in an amber glass bottle with a child-resistant closure.
Child Safety	The medicine must be kept out of the sight and reach of children.

Expired or unused Promazine and its container must be disposed of at an approved waste disposal plant or in accordance with local/regional/national regulations. Regulatory guidance instructs against discarding medicines via wastewater or household waste.